What is CBN? Cannabinol, sleep and current research

Author: Dipl.-Chem. Mohammad Reza Talebnasab
Editorially updated: 12 October 2026

Cannabinol, or CBN, is a cannabinoid compound discussed particularly in relation to cannabis ageing and sleep research. CBN is neither another name for CBD nor automatically a proven sleep medicine. An objective assessment depends on how it forms, the precise composition of the preparations studied and the results of clinical trials.

How does cannabinol form?

CBN can form through the breakdown or oxidation of THC. Cannabis storage studies show that cannabinoid levels can change over time; light and temperature influence these processes. The relationships are more complex than the simplified claim that ‘old cannabis consists only of CBN’. Experimental study of storage and cannabinoid composition

The presence of CBN does not establish that a finished product is THC-free. The specific composition is decisive. A traceable analytical report and the detection limit used must be distinguished from a blanket statement about CBN itself.

CBN's effects: distinguishing laboratory findings from clinical studies

Cannabinol is investigated in various research models. However, a biological effect in cells or an animal experiment initially shows only that something was observed under those experimental conditions. Whether it can lead to a safe and effective treatment in humans must be assessed separately. This distinction is particularly important for claims about sleep, pain, inflammation or seizures.

Our article on the endocannabinoid system explains the biological principles. Not every cannabinoid interacts in the same way with the targets described there.

CBN and sleep: what do human studies show?

A placebo-controlled study by Bonn-Miller and colleagues assessed 293 adults with self-reported sleep problems. Treatment lasted seven nights. The difference between CBN and placebo for the primary endpoint, sleep quality, was not statistically significant. More favourable results were observed for some other measures, such as night-time awakenings and overall sleep disturbance. This is a nuanced finding, not general evidence of a treatment for insomnia. Placebo-controlled sleep study by Bonn-Miller et al.

A crossover study published in 2026 investigated CBN in 20 people with diagnosed insomnia over individual treatment nights. The primary outcome, wake after sleep onset, did not improve statistically significantly compared with placebo. Some secondary sleep parameters were more favourable at one of the doses studied. The small sample and very short study do not support reliable conclusions about longer-term treatment. Lavender et al., 2026

Why a sleep finding does not apply to every CBN product

Comparisons between studies need to consider composition, the amount studied, duration, population and measurement method. A result with one preparation does not automatically apply to another CBN oil or a CBD–CBN mixture. Subjective ratings and objective sleep measurements must also be considered separately.

An improvement in individual measures does not necessarily mean that the central research question was answered positively. Conversely, a non-significant primary endpoint does not mean that every research question has been definitively answered negatively. The results described so far do not justify guarantees of a ‘relaxing night’ or an ‘energetic morning’.

Further research: antibacterial properties

In a laboratory study from 2008, several cannabinoids, including CBN, showed activity against certain Staphylococcus aureus strains. Bacteria were investigated under experimental conditions; infections in humans were not treated. This finding does not make CBN a substitute for antibiotics or medical treatment. Appendino et al., 2008

Claims about pain, epilepsy or inflammation likewise require clinical evidence relevant to the particular condition. Results for CBD, THC or combination preparations cannot simply be attributed to CBN.

CBN: safety and unresolved questions

The human studies described so far are too short and too small to comprehensively assess rare risks, long-term safety or all possible interactions. ‘Plant-based’ does not guarantee safety. Individual medical assessment is important if you have an existing condition, take medicines or have persistent sleep problems.

An analysis of ingredients explains which substances were measured in a tested sample. It does not automatically answer questions about suitable use or a health benefit. This article therefore provides no dosage or treatment recommendations.

Comparing CBN, CBD and CBG

Cannabinol differs from cannabidiol (CBD) and cannabigerol (CBG). The three substances differ chemically and in their scientific evidence base. Comparing them solely through similar advertising claims does not reflect these differences. The history of cannabis provides more information about the plant and its historical use.

Note: this article provides general scientific information. It does not replace diagnosis, medical advice or treatment and contains no dosage or product-use recommendations.

​

​​Further reading: Cannabinoids and medicines: mechanisms and risks of interactions.

Product information: 10% CBN broad-spectrum distillate · Compare CBD–CBN sets.